Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by JayjayUSA12007on May 13, 2018 6:25pm

196 Views

Post# 28024365

Thera US Patents

	PAT. NO.	Title
1	9,334,314	Peptide compounds derived from melanotransferrin and uses thereof
2	9,073,963	Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F.sub.2.alpha. receptor
3	8,871,713	Formulations of growth hormone releasing factor (GRF) molecules with improved stability
4	8,822,413	Bifunctional hormone having alpha-MSH activity and natriuretic peptide activity and uses thereof
5	8,481,489	GH secretagogues and uses thereof
6	8,435,945	GH secretagogues and uses thereof
7	8,361,964	Growth hormone releasing factor (GRF) analogs and uses thereof
8	8,314,066	GH secretagogues and uses thereof
9	7,538,185	Glucagon-like peptide-1 analogs with long duration of action
10	7,521,530	Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F.sub.2.alpha. receptor
11	7,414,029	Antagonistic peptides of prostaglandin E2 receptor subtype EP4
12	7,316,997	GH secretagogues and uses thereof
13	7,094,761	Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
14	7,067,488	Modified GLP-1 peptides with increased biological potency
15	6,864,239	Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
16	6,458,764	GRF analogs with increased biological potency
17	6,194,384	Long-acting galenical formulation for GRF peptides
18	6,106,544	Cutaneous harness for sutureless wound closing
19	6,020,311	GRF analogs with increased biological potency
20	5,939,386	Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency
21	5,861,379	Chimeric fatty body-pro-GRF analogs with increased biological potency
22	5,843,123	Cutaneous harness for sutureless wound closing
23	5,837,204	System for disinfecting the water lines of a dental unit
24	5,834,418	Process for the preparation of platelet growth factors extract
25	5,817,627	Long-acting galenical formulation for GRF peptides
26	5,798,523	Irradiating apparatus using a scanning light source for photodynamic treatment
27	5,602,924	Electronic stethescope
28	D371,604	Sutureless closure for a wound